The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Putative biomarkers of response to anti-PD-1 therapy in metastatic castration-resistant prostate cancer (mCRPC).
 
Khobe Chandran
No Relationships to Disclose
 
Maria Dolores Fenor de la Maza
Honoraria - Roche
Research Funding - Cris Contra el Cancer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Jan Rekowski
No Relationships to Disclose
 
Irene Shui
Employment - Genzyme; Merck
Stock and Other Ownership Interests - Merck; Sanofi
Research Funding - Merck; Merck; Merck; Merck; Sanofi
Travel, Accommodations, Expenses - Merck; Sanofi
 
Bora Gurel
No Relationships to Disclose
 
Pasquale Rescigno
No Relationships to Disclose
 
Emily Cross
No Relationships to Disclose
 
Suzanne Carreira
No Relationships to Disclose
 
Wei Yuan
Travel, Accommodations, Expenses - Jilin Huarui Gene Technology Ltd
 
Ines Figueiredo
No Relationships to Disclose
 
Ana Ferreira
No Relationships to Disclose
 
Mateus Crespo
No Relationships to Disclose
 
Susana Miranda
No Relationships to Disclose
 
Claudia Bertan
No Relationships to Disclose
 
Veronica Gil
No Relationships to Disclose
 
Ruth Riisnaes
No Relationships to Disclose
 
Razvan Cristescu
Employment - Merck
Stock and Other Ownership Interests - Merck
Research Funding - Merck
 
Charles Schloss
Employment - Merck
Stock and Other Ownership Interests - Merck
Research Funding - Merck
 
Christina Yap
Honoraria - Celgene
Consulting or Advisory Role - Faron Pharmaceuticals
Travel, Accommodations, Expenses - Celgene; Faron Pharmaceuticals
 
Johann S. De Bono
Employment - Institute of Cancer Research
Honoraria - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; BioExcel; Boehringer Ingelheim; Celgene; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Medivation; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
Consulting or Advisory Role - Amgen; Astellas Pharma; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
Research Funding - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; CellCentric; Daiichi Sankyo; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Vertex
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Cellcentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex